Bailly F, Si N, Si A, Trepo C
Department of Hepato-Gastroenterology, Hôtel-Dieu, Lyon, France.
Nephrol Dial Transplant. 1996;11 Suppl 4:56-7. doi: 10.1093/ndt/11.supp4.56.
Interferon alpha has confirmed its efficacy for the therapy of chronic hepatitis C. Half of the patients treated will normalize their plasma ALT at the end of a 6-month course of 3 MU thrice a week. This biochemical response is associated with a reduction of HCV RNA (viraemia) from serum and with significant improvement of liver histology. Despite those beneficial effects, 50% of treatment responders generally relapse after treatment arrest. Increasing doses to 6 MU and/or the duration of interferon therapy increases the proportion of long-term sustained responders. Combining therapy with ribavirin, a nucleoside analogue, also appears to have a similar effect.
α干扰素已证实对慢性丙型肝炎的治疗有效。接受治疗的患者中有一半在每周三次、每次300万单位、为期6个月的疗程结束时，其血浆谷丙转氨酶水平会恢复正常。这种生化反应与血清中丙型肝炎病毒RNA（病毒血症）的减少以及肝脏组织学的显著改善相关。尽管有这些有益效果，但50%的治疗有反应者在治疗停止后通常会复发。将干扰素剂量增加至600万单位和/或延长治疗时间可提高长期持续有反应者的比例。将治疗与核苷类似物利巴韦林联合使用似乎也有类似效果。
